Meeting
2021 ASCO Annual Meeting
Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.
Authors
Jason D. Lickliter
Nucleus Network Limited, Melbourne, Australia
Jason D. Lickliter , Ross Jennens , Charlotte Rose Lemech , Ganessan Kichenadasse , Dongpo Cai , Steven Yung-Chang Su
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
ACTRN12616000228482
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2037)
DOI
10.1200/JCO.2021.39.15_suppl.2037
Abstract #
2037
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.
First Author: Yehui Shi
Poster
2021 ASCO Annual Meeting
PF‑06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
First Author: Jordi Rodon Ahnert
Poster
2021 ASCO Annual Meeting
Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).
First Author: Sant P. Chawla
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas